BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 19322705)

  • 1. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation.
    Yan SF; Yan SD; Ramasamy R; Schmidt AM
    Ann Med; 2009; 41(6):408-22. PubMed ID: 19322705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair.
    Rong LL; Gooch C; Szabolcs M; Herold KC; Lalla E; Hays AP; Yan SF; Yan SS; Schmidt AM
    Restor Neurol Neurosci; 2005; 23(5-6):355-65. PubMed ID: 16477098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.
    Bierhaus A; Nawroth PP
    Diabetologia; 2009 Nov; 52(11):2251-63. PubMed ID: 19636529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    Yan SF; Ramasamy R; Schmidt AM
    J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unlocking the biology of RAGE in diabetic microvascular complications.
    Manigrasso MB; Juranek J; Ramasamy R; Schmidt AM
    Trends Endocrinol Metab; 2014 Jan; 25(1):15-22. PubMed ID: 24011512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.
    Leung SS; Forbes JM; Borg DJ
    Curr Diab Rep; 2016 Oct; 16(10):100. PubMed ID: 27612847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RAGE Signaling in Inflammatory Disease.
    Hudson BI; Lippman ME
    Annu Rev Med; 2018 Jan; 69():349-364. PubMed ID: 29106804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.
    Stern D; Yan SD; Yan SF; Schmidt AM
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1615-25. PubMed ID: 12453678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response.
    Clynes R; Moser B; Yan SF; Ramasamy R; Herold K; Schmidt AM
    Curr Mol Med; 2007 Dec; 7(8):743-51. PubMed ID: 18331232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.
    Harja E; Bu DX; Hudson BI; Chang JS; Shen X; Hallam K; Kalea AZ; Lu Y; Rosario RH; Oruganti S; Nikolla Z; Belov D; Lalla E; Ramasamy R; Yan SF; Schmidt AM
    J Clin Invest; 2008 Jan; 118(1):183-94. PubMed ID: 18079965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
    Stern DM; Yan SD; Yan SF; Schmidt AM
    Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment.
    Gasparotto J; Girardi CS; Somensi N; Ribeiro CT; Moreira JCF; Michels M; Sonai B; Rocha M; Steckert AV; Barichello T; Quevedo J; Dal-Pizzol F; Gelain DP
    J Biol Chem; 2018 Jan; 293(1):226-244. PubMed ID: 29127203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycation & the RAGE axis: targeting signal transduction through DIAPH1.
    Shekhtman A; Ramasamy R; Schmidt AM
    Expert Rev Proteomics; 2017 Feb; 14(2):147-156. PubMed ID: 27967251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications.
    Yan SF; Barile GR; D'Agati V; Du Yan S; Ramasamy R; Schmidt AM
    Curr Diab Rep; 2007 Apr; 7(2):146-53. PubMed ID: 17425919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease.
    Schmidt AM; Stern DM
    Front Biosci; 2001 Oct; 6():D1151-60. PubMed ID: 11578972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
    Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
    Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting receptors of advanced glycation end products (RAGE): Preventing diabetes induced cancer and diabetic complications.
    Chhipa AS; Borse SP; Baksi R; Lalotra S; Nivsarkar M
    Pathol Res Pract; 2019 Nov; 215(11):152643. PubMed ID: 31564569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of the receptor for advanced glycation end products and its ligands.
    Schmidt AM; Yan SD; Yan SF; Stern DM
    Biochim Biophys Acta; 2000 Dec; 1498(2-3):99-111. PubMed ID: 11108954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.